- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
Ivosidenib is an IDH1 inhibitor used to treat relapsed/refractory acute myeloid leukemia (AML) patients carrying IDH1 mutations or newly diagno...
Pemigatinib is an FGFR inhibitor used to treat advanced cholangiocarcinoma patients carrying FGFR2 fusion or rearrangement. The treatment cours...
Ivosidenib is an IDH1 inhibitor used to treat relapsed/refractory acute myeloid leukemia (AML) patients carrying IDH1 mutations. The duration o...
Ivosidenib, as a targeted therapy for IDH1 mutant acute myeloid leukemia, usually requires long-term use until disease progression or intolerable...
Ivosidenib, as a targeted therapy for IDH1 mutant acute myeloid leukemia (AML), has clinical effects mainly in inducing differentiation, prolon...
Pemigatinib is a selective FGFR inhibitor mainly used to treat advanced cholangiocarcinoma patients carrying FGFR2 fusion or rearrangement. Its...
Lorlatinib is administered continuously without a fixed course of treatment and needs to be dynamically adjusted based on disease progression a...
The duration of use of Lorviqua mainly depends on disease progression and patient tolerance, and is usually continued until disease progression...
The daily dosage of Lorlatinib depends on the drug specifications and individual patient conditions. The standard dose is 100mg/day, and the sp...
The daily dosage of Lorlatinib should be determined based on the patient's condition and tolerance. The standard dosage is 100mg orally once a ...
